Jupiter Topco LLC Takes $24.27 Million Position in Lumexa Imaging Holdings, Inc. $LMRI

Jupiter Topco LLC purchased a new position in Lumexa Imaging Holdings, Inc. (NASDAQ:LMRI) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 2,151,538 shares of the company’s stock, valued at approximately $24,269,000. Jupiter Topco LLC owned approximately 2.24% of Lumexa Imaging as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Janus Henderson Group PLC increased its holdings in Lumexa Imaging by 5.4% during the 1st quarter. Janus Henderson Group PLC now owns 2,100,356 shares of the company’s stock worth $18,063,000 after purchasing an additional 107,903 shares during the last quarter. T. Rowe Price Investment Management Inc. purchased a new position in shares of Lumexa Imaging during the 4th quarter valued at approximately $37,139,000. Healthcare of Ontario Pension Plan Trust Fund purchased a new position in shares of Lumexa Imaging during the 4th quarter valued at approximately $27,750,000. ArrowMark Colorado Holdings LLC acquired a new stake in shares of Lumexa Imaging during the fourth quarter worth approximately $27,750,000. Finally, Invesco Ltd. bought a new stake in shares of Lumexa Imaging in the fourth quarter worth $26,562,000.

Lumexa Imaging Stock Performance

Shares of LMRI opened at $11.51 on Friday. The stock has a market capitalization of $1.11 billion and a PE ratio of -23.49. The business’s fifty day moving average price is $11.40 and its 200 day moving average price is $10.89. The company has a debt-to-equity ratio of 1.40, a current ratio of 1.44 and a quick ratio of 1.44. Lumexa Imaging Holdings, Inc. has a 12-month low of $6.45 and a 12-month high of $19.45.

Lumexa Imaging (NASDAQ:LMRI) last released its earnings results on Wednesday, August 12th. The company reported $0.20 earnings per share for the quarter, beating the consensus estimate of $0.03 by $0.17. The business had revenue of $264.16 million for the quarter. Lumexa Imaging has set its FY 2026 guidance at 0.710-0.770 EPS. Equities research analysts forecast that Lumexa Imaging Holdings, Inc. will post 0.25 EPS for the current year.

Analyst Upgrades and Downgrades

LMRI has been the topic of a number of research analyst reports. Barclays increased their price objective on shares of Lumexa Imaging from $9.00 to $13.00 and gave the company an “overweight” rating in a research note on Friday. Weiss Ratings raised shares of Lumexa Imaging from a “sell (e)” rating to a “sell (d)” rating in a research report on Thursday, June 25th. Wall Street Zen upgraded shares of Lumexa Imaging from a “hold” rating to a “buy” rating in a research note on Sunday, August 16th. Finally, Deutsche Bank Aktiengesellschaft set a $16.00 price target on shares of Lumexa Imaging in a research report on Thursday, August 13th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Lumexa Imaging has a consensus rating of “Moderate Buy” and a consensus target price of $17.33.

About Lumexa Imaging

We are one of the largest national providers of diagnostic imaging services(1). Our platform is integrated, scalable and has a proven track record of creating value for our stakeholders. As of September 30, 2025, we and our affiliates operated the second largest(1) outpatient imaging center footprint in the United States. It spans 184 centers(2)across 13 states and includes eight joint venture partnerships with health systems. Our centers are in attractive metropolitan statistical areas (“MSAs”).